I first coated UK primarily based HairClone in 2016 on this very submit (authentic model on the backside). Then I interviewed the corporate’s achieved CEO Dr. Paul Kemp a number of occasions.
Note that Mr. Kemp was beforehand CEO of Intercytex and has a long time of expertise in the regenerative medication and hair house.
I wrote one other submit on HairClone’s hair follicle banking service in 2019 and up to date it in 2021.
Update: March 9, 2023
Last week, one in all our readers talked about that HairClone had updated its website. I contacted Dr. Kemp and he confirmed that the refreshed website was launched on February twenty seventh, 2023. And additionally they have a brand new emblem. Moreover, the corporate plans to begin its delayed cell growth service no later than 2024.
HairClone to Start Cell Expansion Service by 2024
In my prior replace from 2021, I discussed HairClone’s aim of commencing its cell growth service in 2022. However, this was delayed within the aftermath of Covid and fundraising associated points. Several days in the past, Dr. Paul Kemp e-mailed me an replace and I’m pasting his electronic mail under:
“Sorry for not replying sooner but I have just returned from annual leave. Yes we have freshened up the website and created a new logo that was inspired by our goal of rebuilding miniaturizing hair follicles. It was launched Feb 27th.
Our banking service continues to increase and we now have had 3 years of successive growth. We have also shown that our cryopreservation technology, as well as preserving the Dermal Papilla (DP) cells that we will use in the treatment we are developing, is also able to cryopreserve the other cell types from the hair follicle such as melanocytes, epithelial cells and bulge stem cells which could be used in other Regenerative Medicine therapies.
Though we are focusing solely on androgenic alopecia at this time, the follicles we are banking remain the property of the patients so this is a valuable way that patients could store considerable numbers of various cell types in a simple outpatient surgical procedure.
As always, we are re-investing revenues from banking to advance the therapy but are still limited by our ability to bring our technology to the clinic by our funding of the GMP manufacturing process needed to use the DP cells in the clinic.
We have developed an effective and reproducible system to increase the number of DP cells over 1,000 fold and have been able to carry out most of the technical transfer stages of this process to a licensed contract manufacturing facility. But we need additional funds in order to complete this technical transfer and enable the manufacturing facility to produce cells for clinical use.
We are looking to increase the number of Banking Associate Clinics that we work with both in the Americas as well as Europe and Asia and we are working to raise new equity funding in 2023. Our aim is to obtain the funds needed and start offering our cell expansion service no later than 2024.“
Update: October 15, 2021
I always assumed that HairClone’s actual hair cloning or hair multiplication procedure was still years away. They have yet to even start human clinical trials. However, when it comes to autologous hair cell multiplication and transplantation, the UK has less stringent guidelines when it comes to testing in humans. Clinicians can offer unlicensed procedures prior to clinical trials. Japan also has some similar favorable regulations.
What an incredible surprise to then find this encouraging new below interview of Dr. Paul Kemp! He is one of the keynote speakers at the upcoming ISHRS 2021 conference. His presentation will be titled:
“The Evolution of the Promise of Hair Cloning: How Hair Cell Cloning will Fit Into Your Practice.”
HairClone will supply its cell growth hair multiplication companies on a choose foundation in sure clinics within the UK beginning in early 2022. Dr. Kemp has consulted with regulators and they’re very supportive of this step. It is a approach to make sure that future costly and prolonged medical trials have a a lot larger probability of success.
“What we are planning to do early next year is offer a cell expansion service.”
— Paul Kemp (at 15.:50 into the under video).
September 8, 2016
During the previous few months, there have been a number of new firms getting into the hair regeneration sector. Today, I learnt about one more new entrant into the field named HairClone that warranted its personal submit. As but, I don’t contemplate HairClone wherever close to as necessary because the established entities such because the RIKEN/Kyocera/Tsuji partnership (Japan); or the Shiseido/Replicel partnership (Japan).
I’ll briefly analyze HairClone through its positives and negatives:
- The famend and broadly revered researcher Dr. Claire Higgins joined HairClone’s advisory board on August thirtieth.
Very excited to welcome Claire Higgins onto our SAB! Claire’s work on dermal papilla cells shall be of nice assist pic.twitter.com/B7ZKhbbHkv
— HairClone (@HairClone) August 30, 2016
- HairClone shall be hiring extra scientific advisers in addition to Dr. Claire Higgins within the close to future. Would be nice in the event that they tried to get Dr. Roland Lauster into the group.
- HairClone has devised a singular and inventive technique to get funding that features: crowdfunding; giving individuals who fund the corporate’s analysis desire when the precise remedy comes out; permitting funding in fairness; providing main hair transplant clinics world wide membership alternatives; and most attention-grabbing of all, hair follicle banking and storage.
- By far the largest unfavourable is that that is nonetheless approach too early within the recreation and who is aware of when trials will start, and whether or not the corporate will succeed with its dermal papilla centered cloning know-how within the first place. Or even when they handle to get adequate funding.
- Related to the above, when Solomon interviewed Dr. Claire Higgins earlier this yr, she usually sounded pessimistic about new therapies and stated the next about cloning. Update: Solomon corrected me within the feedback and stated she was solely speaking about cell injections. But I believe she sounded pessimistic concerning the hair cloning time frame in the entire interview:
“I think the future (but it’s not in 4 years or 5 years away, it’s like in 20 years) is to promote direct conversion of fibroblasts into papillae. But something like this will take decades. We don’t know how to do that yet.”
I’m hoping that Dr. Higgins will change her prediction to 10 years if her lab and analysis work will get considerably extra sources on account of HairClone. Thankfully, she stated that she was not precisely certain about Dr. Tsuji’s work. Neither did she record Shiseido’s trials in Japan in her record of ongoing trial examples. So perhaps she is simply fully centered on her personal work and never following others an excessive amount of?
Twenty years could be too huge a raffle to put money into an organization comparable to HairClone. I hope Dr. Bessam Farjo has different concepts and is hoping for a lot quicker completion of medical trials. And hopefully he isn’t solely counting on Dr. Higgins’ dermal papilla associated work.
Note: The firm web site has some typos, circulate points and appears considerably haphazardly put collectively in the mean time. It even consists of “hello-world” and placeholder kind pages.